| The Emeralds At Faribault Llc | |
| 500 Southeast First Street, Faribault, Minnesota 55021 | |
| (507) 332-5100 | |
| Name | The Emeralds At Faribault Llc |
|---|---|
| Location | 500 Southeast First Street, Faribault, Minnesota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 90 |
| Occupancy Rate | 51.89% |
| Medicare ID (CCN) | 245067 |
| Legal Business Name | The Emeralds At Faribault Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1467926923 |
| Organization Name | THE EMERALDS AT FARIBAULT LLC |
| Address | 500 1st St Se, Faribault, MN 55021 |
| Phone Number | 507-332-5100 |
News Archive
Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system - a network of vessels that transports and stores immune cells throughout the body - to promote the spread of disease, a process called metastasis.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Join BioTek Instruments at the SLAS 2017 Conference and Exhibition to see how their life science instruments and automated systems can increase versatility and efficiency in reading, washing, dispensing and imaging workflows.
CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced clinical results showing meaningful and sustained low clinical events for patients with ischemic heart failure three years following Percutaneous Ventricular Restoration (PVR) therapy with the first-of-its-kind catheter-based Parachute™ Ventricular Partitioning Device.
Peter Hotez, chair of the Department of Microbiology, Immunology, and Tropical Medicine at George Washington University and president of Sabin Vaccine Institute, "will join the staffs of Texas Children's Hospital and Baylor College of Medicine this summer, and will serve as founding dean of a new, as yet unnamed, tropical disease research school at Baylor," the Houston Chronicle reports.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system - a network of vessels that transports and stores immune cells throughout the body - to promote the spread of disease, a process called metastasis.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Join BioTek Instruments at the SLAS 2017 Conference and Exhibition to see how their life science instruments and automated systems can increase versatility and efficiency in reading, washing, dispensing and imaging workflows.
CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced clinical results showing meaningful and sustained low clinical events for patients with ischemic heart failure three years following Percutaneous Ventricular Restoration (PVR) therapy with the first-of-its-kind catheter-based Parachute™ Ventricular Partitioning Device.
Peter Hotez, chair of the Department of Microbiology, Immunology, and Tropical Medicine at George Washington University and president of Sabin Vaccine Institute, "will join the staffs of Texas Children's Hospital and Baylor College of Medicine this summer, and will serve as founding dean of a new, as yet unnamed, tropical disease research school at Baylor," the Houston Chronicle reports.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $10700 |
| Number of Payment Denials | 2 |
| Total Number of Penalties | 3 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.45 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 24.86 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 49.12 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.56 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.93 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.69 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.84 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.58 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 22.17 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 94.25 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.98 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 28.81 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.71 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.08 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.67 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 74.79 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 84.41 | 82.93 |
News Archive
Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system - a network of vessels that transports and stores immune cells throughout the body - to promote the spread of disease, a process called metastasis.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Join BioTek Instruments at the SLAS 2017 Conference and Exhibition to see how their life science instruments and automated systems can increase versatility and efficiency in reading, washing, dispensing and imaging workflows.
CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced clinical results showing meaningful and sustained low clinical events for patients with ischemic heart failure three years following Percutaneous Ventricular Restoration (PVR) therapy with the first-of-its-kind catheter-based Parachute™ Ventricular Partitioning Device.
Peter Hotez, chair of the Department of Microbiology, Immunology, and Tropical Medicine at George Washington University and president of Sabin Vaccine Institute, "will join the staffs of Texas Children's Hospital and Baylor College of Medicine this summer, and will serve as founding dean of a new, as yet unnamed, tropical disease research school at Baylor," the Houston Chronicle reports.
› Verified 2 days ago
The Emeralds At Faribault Llc Location: 500 Southeast First Street, Faribault, Minnesota 55021 Phone: (507) 332-5100 | |